Index	Text	Cause	Effect	Offset_Sentence2	Offset_Sentence3	Cause_Start	Cause_End	Effect_Start	Effect_End	Sentence
0272.00001	Share  September 13, 2019  Rare Daily Staff  Castle Creek Pharmaceutical Holdings, the parent of Castle Creek Pharmaceuticals, has reached an agreement to acquire Fibrocell Science, a cell and gene therapy company developing treatments for skin and connective tissue diseases. Under the terms of the deal, Castle Creek will pay Fibrocell shareholders $3 per share, a 63 percent premium to its 30-day volume all-cash price for a total consideration of approximately $63.3 million, including repayment of debt and other financial instruments, in cash.	Share  September 13, 2019  Rare Daily Staff  Castle Creek Pharmaceutical Holdings, the parent of Castle Creek Pharmaceuticals, has reached an agreement to acquire Fibrocell Science, a cell and gene therapy company developing treatments for skin and connective tissue diseases.	Under the terms of the deal, Castle Creek will pay Fibrocell shareholders $3 per share, a 63 percent premium to its 30-day volume all-cash price for a total consideration of approximately $63.3 million, including repayment of debt and other financial instruments, in cash.	276		0	276	277	549	<e1>Share  September 13, 2019  Rare Daily Staff  Castle Creek Pharmaceutical Holdings, the parent of Castle Creek Pharmaceuticals, has reached an agreement to acquire Fibrocell Science, a cell and gene therapy company developing treatments for skin and connective tissue diseases.</e1> <e2>Under the terms of the deal, Castle Creek will pay Fibrocell shareholders $3 per share, a 63 percent premium to its 30-day volume all-cash price for a total consideration of approximately $63.3 million, including repayment of debt and other financial instruments, in cash.</e2>
